Skip to contentB
Bioxytran, Inc
B
BIXTBioxytran, Inc Q2 2015 · 10-Q
Revenue$59.40K$59.40K+57.0% vs Q2 2014 Net Income-$1.92M-$1.92MN/M vs Q2 2014 EPS Diluted-$0.20-$0.20— vs Q2 2014 Gross Profit$44,676+72.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bioxytran, Inc · CIK 1445815 · Engraved from SEC EDGAR
Operating Cash Flowderived-$7,629N/M Margins · derivedGross margin75.2%+6.9 pt vs Q2 2014
Operating margin-3222.3%−3073.9 pt vs Q2 2014
Net margin-3225.6%−3071.9 pt vs Q2 2014
ended Jun 30, 2015 · filed Aug 19, 2015 · 50 d after period end